ESR2 and medulloblastoma: Since ICI182,780 inhibits both ERα and ERβ, and these two nuclear receptors mediate different and often opposite cellular responses, better understanding of ERβ and its role in normal and pathologic growth of neural progenitors is absolutely required before pharmacological manipulations targeting this nuclear receptor could be used as a clinical regimen against medulloblastoma.